10 most popular complementary medicines may interact with cancer therapy
the ONA take:
According to new research presented at the Clinical Oncology Society of Australia's (COSA's) Annual Scientific Meeting in Melbourne, Australia, researchers at Peter MacCallum Cancer Centre in Melbourne have found that the 10 most asked about complementary medicines all may result in drug interactions with administered with chemotherapy, radiation, or prior to surgery.
For the study, researchers identified the 10 most commonly inquired about complementary medicines by providers and patients to the hospital's Medicines Information Centre. Excluding vitamins and minerals, the 10 most commonly asked about complementary medicines were: astragalus, coenzyme Q10, fish oil, ginger, green tea, lactobacillus, licorice, milk thistle, and reishi mushroom.
The researchers note that any of those found in a normal healthy diet would not likely cause adverse effects, but higher quantities consumed in complementary medicines could. These supplemental medicines have the potential to alter the effects of chemotherapy, thereby increasing the patient's risk of toxicity or decreasing the effectiveness of the chemotherapy.
Products that contain high levels of antioxidants can potentially interact with chemotherapy and radiotherapy. Patients should be aware that a natural product may not be safe and a complementary product does not necessarily complement standard cancer therapies.
10 most asked about complementary medicines all may result in drug interactions.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|